The most serious complication of COVID-19 infection is Acute Respiratory Distress Syndrome (ARDS). More than 40% of seriously hospitalised patients develop ARDS, and about 50% with moderate-severe ARDS die because of it. Taking into account the proven safety and efficacy of mesenchymal cells in diseases that occur with a process of exacerbated inflammation, several groups, including the one led by Dr. Dongcheng Wu in Wuhan (China), have focused their efforts on cell treatment for critically ill COVID-19 patients with promising results.
Histocell y Microdan alcanzan un acuerdo para reforzar la comercialización de Reoxcare en España
More Articles ...
- Reoxcare was very well received at the SGH Congress
- Reoxcare present at the 29th Conference of the European Wound Management Association, EWMA 2019
- Reoxcare continues its growth in the wound care market with the participation in the 8th International Symposium on the Diabetic Foot
- Reoxcare refuerza su presencia en el mercado español en el Congreso SEHER